← Leaderboards
Edwin Manuel
Beckman Research Institute/City Of Hope
$4,288,765
Attributed
$4,288,765
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$4,288,765 · 4
By mechanism
R01$3,382,655 · 2
R21$906,110 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Cancer Therapy”
- Lauren Miller · Technical Resources International, Inc.$31,120,905
- Walt Lee$25,884,232
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Mehrinfar Mahzad · Fisher Bioservices, Inc.$18,271,500
- Michael E. Roth · Public Health Institute$8,201,777
- Cathryn Peltz · Henry Ford Health + Michigan State University Health Sciences$7,977,678
Research focus
Cancer TherapyMalignant NeoplasmsTumorMicrobialNational Cancer InstituteCostProductionCulture MediaNovel StrategiesEngineeringVectorClinical TranslationTumor GrowthMalignant Neoplasm Of PancreasMacromoleculeManualsExtracellular MatrixNeoplasm MetastasisPlasmidsDesign And ConstructionEnzymesMouse ModelPancreatic Ductal AdenocarcinomaClinically Relevant
Grant awards (11)
Microbial- based targeting of major extracellular matrix components for improved therapy of pancreatic cancer$730,400
R01 · FY2025 · CA · contact PI
Development of Microbial-Based Therapies to Suppress Macropinocytosis in Kras-Driven Cancers$402,600
R01 · FY2025 · CA · contact PI
Modulating Intratumoral Immune Composition to Enhance Immunotherapy$457,683
R21 · FY2024 · CA · contact PI
Development of Microbial-Based Therapies to Suppress Macropinocytosis in Kras-Driven Cancers$382,471
R01 · FY2024 · CA · contact PI
Microbial- based targeting of major extracellular matrix components for improved therapy of pancreatic cancer$346,940
R01 · FY2024 · CA · contact PI
Development of Microbial-Based Therapies to Suppress Macropinocytosis in Kras-Driven Cancers$394,548
R01 · FY2023 · CA · contact PI
Microbial- based targeting of major extracellular matrix components for improved therapy of pancreatic cancer$357,896
R01 · FY2023 · CA · contact PI
Utilizing Hybrid Antigen-Presenting Neutrophils to Prime WT1-Specific Immune Responses as Therapy for Acute Leukemia$201,587
R21 · FY2023 · CA · contact PI
Development of Microbial-Based Therapies to Suppress Macropinocytosis in Kras-Driven Cancers$402,600
R01 · FY2022 · CA · contact PI
Microbial- based targeting of major extracellular matrix components for improved therapy of pancreatic cancer$365,200
R01 · FY2022 · CA · contact PI
Utilizing Hybrid Antigen-Presenting Neutrophils to Prime WT1-Specific Immune Responses as Therapy for Acute Leukemia$246,840
R21 · FY2022 · CA · contact PI